Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

This study has been completed.
Sponsor:
Information provided by:
Chugai Pharma USA
ClinicalTrials.gov Identifier:
NCT00055510
First received: March 4, 2003
Last updated: June 23, 2005
Last verified: February 2004
  Purpose

This research study is intended to evaluate the safety and effectiveness of 3 different doses of BO-653, an investigational inhibitor of LDL cholesterol oxidation, when given orally twice a day compared to placebo (an inactive substance) in preventing restenosis (closure of vessel) within six months after stent implantation. Patients must be enrolled into this study within 24 hours after the stenting procedure.

Additionally, over a 1- to 9-month post-stent period, the study will compare the safety and effectiveness of BO-653 versus placebo for measures of coronary artery vessel size by quantitative coronary angiography, major adverse cardiac events, and effects on the oxidative status of plasma lipids and other plasma components.


Condition Intervention Phase
Graft Occlusion, Vascular
Coronary Restenosis
Atherosclerosis
Drug: BO-653
Phase 2
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Chugai Pharma USA:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Major Inclusion Criteria – Others Stipulated within the Protocol

The study physician must assure you:

  • Are at least 18 years of age and have achieved a successful stent placement procedure as defined by ≤ 10% residual stenosis, no residual dissection, TIMI flow > 3 (complete perfusion), and lack of procedural coronary perforation utilizing an FDA-approved stent, excluding self-expanding, coil, polymer and pharmacologic coated (heparin OK) stents.
  • Have at least one untreated target lesion in a native coronary artery meeting study entry criteria for diameter (≥ 2.5mm and ≤ 3.5mm), stenosis (≥ 50% and < 100%), and stent length (≥ 13mm and ≤ 36mm, or total of two stents ≤ 45mm).
  • Have a documented history of angina pectoris or a positive functional study.
  • Have no symptoms suggestive of an MI (heart attack) OR have cardiac isoenzymes (CK-MB) within normal range at least 24 hours prior to stent procedure.
  • Use effective birth control measures, or are unable to conceive children.
  • Are willing to have a repeat angiogram after 6 months.

Major Exclusion Criteria – Others Stipulated within the Protocol

The study physician must assure you:

  • Have not had any coronary intervention within 30 days before, and for an expected 30 days after stenting.
  • Have not had a cerebrovascular accident or transient ischemic attack within 90 days prior to stent placement.
  • Have not had stent procedure as a bridge to non-emergency planned bypass.
  • Have not had a stent placed within the target vessel less than 9 months ago, or less than 5mm from the closest edge of an adjacent lesion.
  • Do not have an unprotected left main coronary artery disease.
  • Do not have a left ventricular ejection fraction of < 30%.
  • Do not have a target lesion that is located at the ostium (< 2mm from origin of left anterior descending, right coronary artery, or circumflex vessel), involves a side branch ≥2.0mm diameter, is moderately to severely calcified, or requires use of an atherectomy device.
  • Have not had a heart transplant.
  • Do not have a 12-lead ECG with a QTc interval pre- or post stent placement ≥ 460 msec (males), or ≥ 470 msec (females).
  • Do not have any medical, surgical or psychiatric condition, or be medical unstable as would prevent you from safely participating in the trial.
  • Do not have clinically relevant bleeding, clotting, or immune disorders or be intolerant of platelet inhibitors and/or anticoagulants.
  • Are not taking rifampin, carbamazepine, phenobarbitol, cyclophosphamide, ifosfamide, artemisinin, mephenytoin, phenytoin, or cholestyramine.
  • Have no clinically significant laboratory abnormality (specified: creatinine ≥ 2.2 mg/dl, liver function tests ≥ 2.0 times the upper limit of normal).
  • Have not participated in any investigational study within past 30 days.
  • Are not allergic or intolerant to soybean products.
  • Are not taking vitamin E in excess of 150 I.U. per day and that you are unwilling to stop.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00055510

  Hide Study Locations
Locations
United States, Arizona
St. Luke's Medical Center
Phoenix, Arizona, United States, 85006
University of Arizona Sarver Heart Center
Tucson, Arizona, United States, 85724
United States, California
Cardiovascular Associates of the Peninsula
Burlingame, California, United States, 94010
Foundation for Cardiovascular Medicine
La Jolla, California, United States, 92037
La Mesa Cardiac Center
La Mesa, California, United States, 91942
Clinical Research Center of California
San Diego, California, United States, 92117
Veterans Affairs Medical Center
San Diego, California, United States, 92161
United States, Florida
University of Florida Health Science Center
Jacksonville, Florida, United States, 32209
Miami International Cardiology Consultants
Miami Beach, Florida, United States, 33140
Mediquest Research Group
Ocala, Florida, United States, 34474
United States, Illinois
Midwest Heart Research Foundation
Lombard, Illinois, United States, 60148
United States, Iowa
Iowa Heart Center
Des Moines, Iowa, United States, 50314
United States, Louisiana
Alton Ochsner Medical Foundation
New Orleans, Louisiana, United States, 70121
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Baystate Medical Center
Springfield, Massachusetts, United States, 01199
United States, Michigan
Borgess Medical Center
Kalamazoo, Michigan, United States, 49048
Michigan Heart
Ypsilanti, Michigan, United States, 48197
United States, Minnesota
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States, 55407
United States, Missouri
St. Louis University
St. Louis, Missouri, United States, 63110
United States, Nevada
Nevada Cardiology Associates
Las Vegas, Nevada, United States, 89109
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14642
United States, North Carolina
Asheville Cardiology Associates, PA
Asheville, North Carolina, United States, 28803
United States, Ohio
Northwestern Memorial Hospital
Elyria, Ohio, United States, 44035
United States, Oklahoma
Oklahoma Foundation for Cardiovascular Research
Oklahoma City, Oklahoma, United States, 73120
United States, Texas
Austin Heart
Austin, Texas, United States, 78756
IRCI Institute for Research in Cardiovascular Interventions at The Methodist DeBakey Heart Center
Houston, Texas, United States, 77030
University of Texas Health Science Center
San Antonio, Texas, United States, 78229-3900
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
Chugai Pharma USA
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00055510     History of Changes
Other Study ID Numbers: BO-004
Study First Received: March 4, 2003
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by Chugai Pharma USA:
BO-653
Coronary restenosis
Stent restenosis
LDL oxidative inhibitor
Antioxidant

Additional relevant MeSH terms:
Arteriosclerosis
Atherosclerosis
Coronary Restenosis
Graft Occlusion, Vascular
Arterial Occlusive Diseases
Cardiovascular Diseases
Coronary Disease
Coronary Stenosis
Heart Diseases
Myocardial Ischemia
Pathologic Processes
Postoperative Complications
Vascular Diseases

ClinicalTrials.gov processed this record on November 25, 2014